Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Histone H3/H3C15 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Histone H3/H3C15 WT & Mutant (e.g., K27M, K36M) Recombinant Proteins High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for SPR/crystallography. |
View Histone H3 Products |
| Gene Delivery | Histone H3/H3C15 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and chromatin remodeling assays. |
View Histone H3 Products |
| Benchmark Ab | Anti-Histone H3 Recombinant Antibody Recombinant positive control for ChIP-qPCR, Western Blot, and ELISA assays. |
View Histone H3 Products |
| Validator | Histone H3/H3C15 siRNA Set For target knockdown verification and functional genomics validation. |
View Histone H3 Products |
| Related Target A | EZH2 Primary methyltransferase responsible for H3K27me3; critical co-target in epigenetic oncology. |
View EZH2 Products |
| Related Target B | WDR5 WD40-repeat protein that interacts with Histone H3; key target for disrupting the MLL/SET methyltransferase complex. |
View WDR5 Products |
| Related Target C | Menin Critical reader for H3 modification complexes; pivotal in MLL-rearranged leukemias. |
View Menin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing mutant Histone H3 (e.g., K27M) from Wild-Type | Sequence-verified mutant and wild-type proteins with precise theoretical MW verification. |
| Nucleosome reconstitution and chromatin assembly | High-purity monomeric histones (>95% by SDS-PAGE) with strict endotoxin control. |
| Specific PTM recognition (e.g., mono-, di-, tri-methylation) | Recombinant proteins with defined post-translational modifications, verified by mass spectrometry. |
| Lack of reliable assay reference standards / Controls | Sequence-defined recombinant benchmark antibodies and validated siRNA included for assay calibration and specificity checks. |
| Off-target screening against other histone variants | Homolog panel proteins available, verified by mass spectrometry and high-resolution chromatography. |
Live Histone H3/H3C15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Histone H3/H3C15 therapeutics is intensifying, with major players shifting focus from traditional global epigenetic modifiers to targeted approaches: mutant-specific targeting, protein-protein interaction (PPI) disruptors, and combination epigenetic therapies. As first-generation chromatin-modifying therapies reach the clinic, the next wave of R&D is targeting specific oncogenic histone mutations (such as H3K27M in diffuse intrinsic pontine glioma and pediatric gliomas) and the physical interaction interfaces between Histone H3 and its chaperones or writers. Combination with immunotherapies (e.g., PD-1/PD-L1 blockers) to remodel chromatin accessibility and reactivate endogenous retroviruses is an emerging hot spot.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors & traditional) | Incyte, Pfizer, Boehringer Ingelheim, Epizyme, Syndax | Solid Tumors, MLL-rearranged Leukemias, Hematological Malignancies | Biophysical Binding & Selectivity Assays (Need high-purity, natively folded H3 tail peptides/proteins; mutant vs WT proteins) |
| TCR-T / Immunotherapy | Immatics, Adaptimmune | H3K27M-mutant Gliomas | MHC-peptide binding validation (Need sequence-verified mutant peptides and control constructs) |
| PROTACs / Degraders | Arvinas, Kymera | Solid Tumors | Degradation Assays (Need high-purity recombinant targets and stable cell lines) |
| Epigenetic Editors (CRISPR-based) | Sangamo Therapeutics, Editas Medicine | Genetic Disorders, Refractory Cancers | Target engagement and chromatin state monitoring (Need stable cell lines via Lentivirus delivery) |